This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
=== Structure === Honokiol belongs to a class of neolignan biphenols. As a polyphenol it is relatively small and can interact with cell membrane proteins through intermolecular interactions like hydrogen bonding, hydrophobic interactions, or aromatic pi orbital co-valency. It is hydrophobic and readily dissolved in lipids. It is structurally similar to propofol.
== Plot == Half Bad is set in a version of modern-day Europe, mainly Britain, in which witches and humans (Fains) live together. Witches are divided into Black (oppressed and written off as evil), and White, the latter making up the majority of the witch population. The 17-year-old protagonist, Nathan, is half White and half Black, or Half Code. His mother is dead, and his father, Marcus, is the most powerful and violent Black witch in history. Because of his parentage, Nathan's every move is monitored by the Council of White Witches. He is forced to follow a strict set of rules, but when he breaks one too many, he is taken away from his grandmother and entrusted into the care of a White witch, Celia. Trapped in a cage and abused by Celia, Nathan must escape before his seventeenth birthday, to find his father, and receive three gifts from him and his Gift. Otherwise, he will die.
Anaerobic bacteria collection can come from a variety of sources in patient samples, including blood, bile, bone marrow, cerebrospinal fluid, direct lung aspirate, tissue biopsies from a normally sterile site, fluid from a normally sterile site (like a joint), dental, abscess, abdominal or pelvic abscess, knife, gunshot, or surgical wound, or severe burn.
Reviews of the literature have found no consistent findings to support such concerns, and, while high doses of aspartame consumption may have some biochemical effects, these effects are not seen in toxicity studies to suggest aspartame can adversely affect neuronal function. As with methanol and aspartic acid, common foods in the typical diet, such as milk, meat, and fruits, will lead to ingestion of significantly higher amounts of phenylalanine than would be expected from aspartame consumption.
=== 20th century === 1901 Walter Kaufmann uses a mass spectrometer to measure the relativistic mass increase of electrons. 1905 J. J. Thomson begins his study of positive rays. 1906 Thomson is awarded the Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases" 1913 Thomson is able to separate particles of different mass-to-charge ratios. He separates the 20Ne and the 22Ne isotopes, and he correctly identifies the m/z = 11 signal as a doubly charged 22Ne particle. 1919 Francis Aston constructs the first velocity focusing mass spectrograph with mass resolving power of 130. 1922 Aston is awarded the Nobel Prize in chemistry "for his discovery, by means of his mass spectrograph, of isotopes, in a large number of non-radioactive elements, and for his enunciation of the whole-number rule." 1931
Sources: en.wikipedia.org
== Applications == Freeze-drying (lyophilization) cycle development and optimization for pharmaceuticals. Flow diagnostics in hypersonic/re-entry speed research facilities and scramjet combustors. Oxygen tunable diode laser spectrometers play an important role in safety applications in a wide range of industrial processes, for this reason, TDLS are often an integral part of modern chemical plants. The fast response time compared to other technologies for measuring gas composition, and the immunity to many background gasses and environmental conditions makes TDL technology a commonly selected technology for monitoring of combustible gasses in process environments. This technology is employed on flares, in vessel headspace and in other locations where explosive atmospheres must be prevented from forming. According to a 2018 research study, TDL technology is the 4th most commonly selected technology for gas analysis in Chemical Processing.
A detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin). (NCI) Case report form
In her autobiography, Out of the Shadows, Anne Marie reflects on how when she asked why her mother had collected Charmaine — who was part-Pakistani, while Anne Marie was fully white — but not her, Fred callously replied: "She wouldn't want you, love. You're the wrong colour." Charmaine's body was initially stowed in the coal cellar of Midland Road until Fred was released from prison. He later buried her naked body in the yard close to the back door of the flat, and remained adamant that he had not dismembered her. A subsequent post-mortem suggested the body had been severed at the hip, but that this damage may have been caused by building work Fred conducted at the property in 1976. Several bones—particularly patellae, finger, wrist, toe and ankle bones—were missing from Charmaine's skeleton, leading to speculation that the missing parts had been retained as keepsakes. This trait would prove to be a distinctive finding in all the autopsies of the Wests' victims when they were exhumed in 1994.
=== Frequently consumed insect species === Human consumption of 2,205 different insect species has been documented. The table below ranks insect order by number and percentage of confirmed species consumed and presents each insect orders' percentage of known insect species diversity. With the exceptions of orders Orthoptera and Diptera, there is close alignment between species diversity and consumption, suggesting that humans tend to eat those insects that are most available.
Sources: en.wikipedia.org
Legio I I Armeniaca I Flavia Constantia (reliable Flavian): comitatensis unit under the command of the Magister militum per Orientis I Flavia Gallicana Constantia (reliable Flavian legion from Gallia): pseudocomitatensis under the command of the Magister Peditum per Gallias. The legion was founded by Constantius I Chlorus. The legions objective was to protect the Armorican coast and fight the Roman-British usurper, Allectus. I Flavia Martis (Flavian legion devoted to Mars): pseudocomitatensis. The legion was founded by Constantius Chlorus to fight Allectus. It was stationed in Gaul. I Flavia Pacis (Flavian legion of peace): comitatensis under the command of the Magister Peditum I Flavia Theodosiana: comitatensis. I Illyricorum (of the Illyrians): stationed at the Camp of Diocletian in Palmyra I Iovia (devoted to Jupiter): levied by Diocletian, stationed at Noviodunum in Scythia Minor I Isaura Sagittaria (archers from Isauria): pseudocomitatensis under the command of the Magister militum per Orientis I Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum in Italy. It is unknown who founded the legion although it was probably Crispus or Constans. I Martia possibly based near modern Kaiseraugst. The Legion could have had the surname Victrix. The legion was probably founded by Diocletian. It also may have built forts in Valeria. I Maximiana Thaebanorum (the Thebans of Maximianus): comitatensis unit stationed near Thebes, Egypt, and probably fighting in the battle of Adrianople I Noricorum (of the Noricans): stationed in Noricum.
==== Rome ==== Potassium alum was described under the name alumen or salsugoterrae by Pliny, and it is clearly the same as the stypteria (στυπτηρία) described by Dioscorides. However, the name alum and other names applied to this substance — like misy, sory, chalcanthum, and atramentum sutorium — were often applied to other products with vaguely similar properties or uses, such as iron sulfate or "green vitriol".
=== General features === Some general architectural features of the ribosome are conserved across kingdoms: The structure of the small subunit can be sub-divided into two large segments, the head and the body. Characteristic features of the body include the left and right feet, the shoulder and the platform. The head features a pointed protrusion reminiscent of a bird's beak. In the characteristic "crown view" of the large subunit, structural landmarks include the central protuberance, the L1-stalk and the P-stalk. The majority of the eukaryote-specific RNA and protein elements are found on the solvent-exposed sides of the 40S and 60S subunits. The subunit interface, as well as important functional regions such as the peptidyl transferase center and the decoding site are mostly conserved, with some differences observed in the surrounding regions. In stark contrast to prokaryotic ribosomal proteins, which interact primarily with RNA, the eukaryote-specific protein segments engage in a multitude of protein-protein interactions. Long-distance interactions are mediated by eukaryote-specific helical extensions of ribosomal proteins, and several eukaryotic ribosomal proteins jointly to form inter-protein beta-sheets.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.